Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 136

1.

Mechanism of stimulation of DNA binding of the transcription factors by human apurinic/apyrimidinic endonuclease 1, APE1.

Bazlekowa-Karaban M, Prorok P, Baconnais S, Taipakova S, Akishev Z, Zembrzuska D, Popov AV, Endutkin AV, Groisman R, Ishchenko AA, Matkarimov BT, Bissenbaev A, Le Cam E, Zharkov DO, Tudek B, Saparbaev M.

DNA Repair (Amst). 2019 Oct;82:102698. doi: 10.1016/j.dnarep.2019.102698. Epub 2019 Aug 31.

PMID:
31518879
2.

Involvement of G-quadruplex regions in mammalian replication origin activity.

Prorok P, Artufel M, Aze A, Coulombe P, Peiffer I, Lacroix L, Guédin A, Mergny JL, Damaschke J, Schepers A, Ballester B, Méchali M.

Nat Commun. 2019 Jul 22;10(1):3274. doi: 10.1038/s41467-019-11104-0.

3.

Metazoan DNA replication origins.

Ganier O, Prorok P, Akerman I, Méchali M.

Curr Opin Cell Biol. 2019 Jun;58:134-141. doi: 10.1016/j.ceb.2019.03.003. Epub 2019 Jun 11. Review.

PMID:
31200185
4.

Overall mortality in men and women in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.

Pinsky PF, Miller EA, Zhu CS, Prorok PC.

J Med Screen. 2019 Sep;26(3):127-134. doi: 10.1177/0969141319839097. Epub 2019 Apr 3. No abstract available.

PMID:
30943843
5.

Physicochemical and antioxidative properties of Cornelian cherry beer.

Kawa-Rygielska J, Adamenko K, Kucharska AZ, Prorok P, Piórecki N.

Food Chem. 2019 May 30;281:147-153. doi: 10.1016/j.foodchem.2018.12.093. Epub 2019 Jan 3.

PMID:
30658741
6.

Effect of flexible sigmoidoscopy screening on colorectal cancer incidence and mortality: long-term follow-up of the randomised US PLCO cancer screening trial.

Miller EA, Pinsky PF, Schoen RE, Prorok PC, Church TR.

Lancet Gastroenterol Hepatol. 2019 Feb;4(2):101-110. doi: 10.1016/S2468-1253(18)30358-3. Epub 2018 Nov 29.

7.

Extended follow-up for prostate cancer incidence and mortality among participants in the Prostate, Lung, Colorectal and Ovarian randomized cancer screening trial.

Pinsky PF, Miller E, Prorok P, Grubb R, Crawford ED, Andriole G.

BJU Int. 2019 May;123(5):854-860. doi: 10.1111/bju.14580. Epub 2018 Nov 2.

PMID:
30288918
8.

Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials.

Prorok PC, Miller AB.

Ann Intern Med. 2018 Apr 17;168(8):605-606. doi: 10.7326/L17-0735. No abstract available.

PMID:
29677259
9.

Overall and Multiphasic Findings of the Prostate, Lung, Colorectal and Ovarian (PLCO) Randomized Cancer Screening Trial.

Prorok PC, Wright P, Riley TR, Kramer BS, Berg CD, Gohagan JK.

Rev Recent Clin Trials. 2018;13(4):257-273. doi: 10.2174/1574887113666180409153059.

PMID:
29629665
10.

Editorial: Challenges in Quantifying Overdiagnosis.

Baker SG, Prorok PC, Kramer BS.

J Natl Cancer Inst. 2017 Oct 1;109(10). doi: 10.1093/jnci/djx064. No abstract available.

11.

Histone H4K20 tri-methylation at late-firing origins ensures timely heterochromatin replication.

Brustel J, Kirstein N, Izard F, Grimaud C, Prorok P, Cayrou C, Schotta G, Abdelsamie AF, Déjardin J, Méchali M, Baldacci G, Sardet C, Cadoret JC, Schepers A, Julien E.

EMBO J. 2017 Sep 15;36(18):2726-2741. doi: 10.15252/embj.201796541. Epub 2017 Aug 4.

12.

Prostate Cancer Screening.

Pinsky PF, Prorok PC, Kramer BJ.

N Engl J Med. 2017 Jun 15;376(24):2402. doi: 10.1056/NEJMc1705480. No abstract available.

PMID:
28614680
13.

Data sharing in clinical trials: An experience with two large cancer screening trials.

Zhu CS, Pinsky PF, Moler JE, Kukwa A, Mabie J, Rathmell JM, Riley T, Prorok PC, Berg CD.

PLoS Med. 2017 May 23;14(5):e1002304. doi: 10.1371/journal.pmed.1002304. eCollection 2017 May.

14.

Prostate Cancer Screening - A Perspective on the Current State of the Evidence.

Pinsky PF, Prorok PC, Kramer BS.

N Engl J Med. 2017 Mar 30;376(13):1285-1289. doi: 10.1056/NEJMsb1616281. No abstract available.

PMID:
28355509
15.

Breast-Cancer Tumor Size and Screening Effectiveness.

Welch HG, Prorok PC, Kramer BS.

N Engl J Med. 2017 Jan 5;376(1):94-5. doi: 10.1056/NEJMc1614282. No abstract available.

PMID:
28052230
16.

Extended mortality results for prostate cancer screening in the PLCO trial with median follow-up of 15 years.

Pinsky PF, Prorok PC, Yu K, Kramer BS, Black A, Gohagan JK, Crawford ED, Grubb RL, Andriole GL.

Cancer. 2017 Feb 15;123(4):592-599. doi: 10.1002/cncr.30474. Epub 2016 Dec 1.

17.

Extended mortality results for ovarian cancer screening in the PLCO trial with median 15years follow-up.

Pinsky PF, Yu K, Kramer BS, Black A, Buys SS, Partridge E, Gohagan J, Berg CD, Prorok PC.

Gynecol Oncol. 2016 Nov;143(2):270-275. doi: 10.1016/j.ygyno.2016.08.334. Epub 2016 Sep 9.

18.

More on Reevaluating PSA Testing Rates in the PLCO Trial.

Pinsky P, Prorok P.

N Engl J Med. 2016 Oct 13;375(15):1500-1501. doi: 10.1056/NEJMc1607379. No abstract available.

PMID:
27732807
19.

Breast-Cancer Tumor Size, Overdiagnosis, and Mammography Screening Effectiveness.

Welch HG, Prorok PC, O'Malley AJ, Kramer BS.

N Engl J Med. 2016 Oct 13;375(15):1438-1447.

20.

Active follow-up versus passive linkage with cancer registries for case ascertainment in a cohort.

Pinsky PF, Yu K, Black A, Huang WY, Prorok PC.

Cancer Epidemiol. 2016 Dec;45:26-31. doi: 10.1016/j.canep.2016.09.003. Epub 2016 Sep 26.

21.

PLCO: Evolution of an Epidemiologic Resource and Opportunities for Future Studies.

Black A, Huang WY, Wright P, Riley T, Mabie J, Mathew S, Ragard L, Hermansen S, Yu K, Pinsky P, Prorok PC, Freedman ND, Hoover RN.

Rev Recent Clin Trials. 2015;10(3):238-45. Review.

22.

Managing Multi-Center Recruitment in the PLCO Cancer Screening Trial.

Gohagan JK, Broski K, Gren LH, Fouad MN, Higgins D, Lappe K, Ogden S, Shambaugh V, Pinsky PF, O'Brien B, Yurgalevich S, Riley T, Wright P, Prorok PC.

Rev Recent Clin Trials. 2015;10(3):187-93. Review.

PMID:
26435288
23.

Study designs for determining and comparing sensitivities of disease screening tests.

Prorok PC, Kramer BS, Miller AB.

J Med Screen. 2015 Dec;22(4):213-20. doi: 10.1177/0969141315600003. Epub 2015 Sep 22.

PMID:
26396138
24.

Building Successful Relationships in the PLCO Cancer Screening Trial.

Marcus PM, Broski KG, Buys SS, Childs J, Church TR, Gohagan JK, Gren LH, Higgins D, Jaggi R, Jenkins V, Johnson CC, Lappe K, O'Brien B, Ogden SL, Prorok PC, Reding D, Shambaugh V, Yokochi LA, Yurgalevitch S.

Rev Recent Clin Trials. 2015;10(3):181-6. Review.

25.

Changes in and Impact of the Death Review Process in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial.

Miller AB, Feld R, Fontana R, Gohagan JK, Jatoi I, Lawrence W Jr, Miller A, ProroK PC, Rajput A, Sherman M, Welch G, Wright P, Yurgalevitch S, Albertsen P.

Rev Recent Clin Trials. 2015;10(3):206-11. Review.

PMID:
26238119
26.

Comprehensive Quality Management (CQM) in the PLCO Trial.

Gohagan JK, O'Brien B, Hasson MA, Umbel KD, Bridgeman B, Kramer BS, Reding D, Gren L, Wright P, Riley T, Prorok PC.

Rev Recent Clin Trials. 2015;10(3):223-32.

PMID:
26238118
27.

Data Processing and Analytic Support in the PLCO Cancer Screening Trial.

Mabie J, Riley T, Marcus PM, Black A, Rozjabek H, Yu K, Young M, Austin J, Rathmell J, Williams C, Prorok PC.

Rev Recent Clin Trials. 2015;10(3):233-7. Review.

PMID:
26238116
28.

The PLCO Cancer Screening Trial: Background, Goals, Organization, Operations, Results.

Gohagan JK, Prorok PC, Greenwald P, Kramer BS.

Rev Recent Clin Trials. 2015;10(3):173-80. Review.

PMID:
26238115
29.

Quantification of length-bias in screening trials with covariate-dependent test sensitivity.

Heltshe SL, Kafadar K, Prorok PC.

Biom J. 2015 Sep;57(5):777-96. doi: 10.1002/bimj.201400152. Epub 2015 May 15.

PMID:
25980962
30.

Screening for cancer: lessons learned from the prostate, lung, colorectal, and ovarian cancer screening trial.

Grubb RL, Pinsky P, Prorok PC, Andriole GL.

Eur Urol. 2015 Oct;68(4):545-6. doi: 10.1016/j.eururo.2015.04.026. Epub 2015 May 8.

PMID:
25959167
31.

Occurrence of Distal Colorectal Neoplasia Among Whites and Blacks Following Negative Flexible Sigmoidoscopy: An Analysis of PLCO Trial.

Laiyemo AO, Doubeni C, Pinsky PF, Doria-Rose VP, Bresalier R, Hickey T, Riley T, Church TR, Weissfeld J, Schoen RE, Marcus PM, Prorok PC.

J Gen Intern Med. 2015 Oct;30(10):1447-53. doi: 10.1007/s11606-015-3297-3. Epub 2015 Apr 3.

32.

Differential repair of etheno-DNA adducts by bacterial and human AlkB proteins.

Zdżalik D, Domańska A, Prorok P, Kosicki K, van den Born E, Falnes PØ, Rizzo CJ, Guengerich FP, Tudek B.

DNA Repair (Amst). 2015 Jun;30:1-10. doi: 10.1016/j.dnarep.2015.02.021. Epub 2015 Mar 5.

33.

Conceptualizing overdiagnosis in cancer screening.

Marcus PM, Prorok PC, Miller AB, DeVoto EJ, Kramer BS.

J Natl Cancer Inst. 2015 Feb 6;107(4). pii: djv014. doi: 10.1093/jnci/djv014. Print 2015 Apr.

34.

Lead time and overdiagnosis.

Baker SG, Prorok PC, Kramer BS.

J Natl Cancer Inst. 2014 Oct 31;106(12). pii: dju346. doi: 10.1093/jnci/dju346. Print 2014 Dec. No abstract available. Erratum in: J Natl Cancer Inst. J Natl Cancer Inst. 2015 Mar;107(3):doi/10.1093/jnci/djv019.

PMID:
25362702
35.

Interval lung cancers not detected on screening chest X-rays: How are they different?

Kvale PA, Johnson CC, Tammemägi M, Marcus PM, Zylak CJ, Spizarny DL, Hocking W, Oken M, Commins J, Ragard L, Hu P, Berg C, Prorok P.

Lung Cancer. 2014 Oct;86(1):41-6. doi: 10.1016/j.lungcan.2014.07.013. Epub 2014 Jul 24.

36.

Cloning and characterization of a wheat homologue of apurinic/apyrimidinic endonuclease Ape1L.

Joldybayeva B, Prorok P, Grin IR, Zharkov DO, Ishenko AA, Tudek B, Bissenbaev AK, Saparbaev M.

PLoS One. 2014 Mar 25;9(3):e92963. doi: 10.1371/journal.pone.0092963. eCollection 2014. Erratum in: PLoS One. 2014;9(6):e101795.

37.

Considerations in the design of randomized trials to screen for type 2 diabetes.

Echouffo-Tcheugui JB, Prorok PC.

Clin Trials. 2014 Jun;11(3):284-291. doi: 10.1177/1740774513517062.

PMID:
24459176
38.

The prostate, lung, colorectal, and ovarian cancer screening trial and its associated research resource.

Zhu CS, Pinsky PF, Kramer BS, Prorok PC, Purdue MP, Berg CD, Gohagan JK.

J Natl Cancer Inst. 2013 Nov 20;105(22):1684-93. doi: 10.1093/jnci/djt281. Epub 2013 Oct 10. Review.

39.

Uracil in duplex DNA is a substrate for the nucleotide incision repair pathway in human cells.

Prorok P, Alili D, Saint-Pierre C, Gasparutto D, Zharkov DO, Ishchenko AA, Tudek B, Saparbaev MK.

Proc Natl Acad Sci U S A. 2013 Sep 24;110(39):E3695-703. doi: 10.1073/pnas.1305624110. Epub 2013 Sep 10.

40.

Diagnostic evaluation following a positive lung screening chest radiograph in the Prostate, Lung, Colorectal, Ovarian (PLCO) Cancer Screening Trial.

Hocking WG, Tammemagi MC, Commins J, Oken MM, Kvale PA, Hu P, Ragard LR, Riley TL, Pinsky P, Beck TM, Prorok PC.

Lung Cancer. 2013 Nov;82(2):238-44. doi: 10.1016/j.lungcan.2013.07.017. Epub 2013 Aug 7.

41.

Assessing the risk of ovarian malignancy in asymptomatic women with abnormal CA 125 and transvaginal ultrasound scans in the prostate, lung, colorectal, and ovarian screening trial.

Partridge EE, Greenlee RT, Riley TL, Commins J, Ragard L, Xu JL, Buys SS, Prorok PC, Fouad MN.

Obstet Gynecol. 2013 Jan;121(1):25-31. doi: http://10.1097/AOG.0b013e3182755e14.

42.

Highly mutagenic exocyclic DNA adducts are substrates for the human nucleotide incision repair pathway.

Prorok P, Saint-Pierre C, Gasparutto D, Fedorova OS, Ishchenko AA, Leh H, Buckle M, Tudek B, Saparbaev M.

PLoS One. 2012;7(12):e51776. doi: 10.1371/journal.pone.0051776. Epub 2012 Dec 14. Erratum in: PLoS One. 2013;8(7). doi:10.1371/annotation/861eeca8-8296-46b7-8bdf-947a0c8db4fa.

43.

Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy.

Schoen RE, Pinsky PF, Weissfeld JL, Yokochi LA, Church T, Laiyemo AO, Bresalier R, Andriole GL, Buys SS, Crawford ED, Fouad MN, Isaacs C, Johnson CC, Reding DJ, O'Brien B, Carrick DM, Wright P, Riley TL, Purdue MP, Izmirlian G, Kramer BS, Miller AB, Gohagan JK, Prorok PC, Berg CD; PLCO Project Team.

N Engl J Med. 2012 Jun 21;366(25):2345-57. doi: 10.1056/NEJMoa1114635. Epub 2012 May 21.

44.

Colorectal cancers not detected by screening flexible sigmoidoscopy in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.

Schoen RE, Pinsky PF, Weissfeld JL, Yokochi LA, Church T, Laiyemo AO, Bresalier R, Hickey T, Riley T, Prorok PC.

Gastrointest Endosc. 2012 Mar;75(3):612-20. doi: 10.1016/j.gie.2011.10.024.

PMID:
22341106
45.

Flexible sigmoidoscopy in the randomized prostate, lung, colorectal, and ovarian (PLCO) cancer screening trial: added yield from a second screening examination.

Weissfeld JL, Schoen RE, Pinsky PF, Bresalier RS, Doria-Rose VP, Laiyemo AO, Church T, Yokochi LA, Yurgalevitch S, Rathmell J, Andriole GL, Buys S, Crawford ED, Fouad M, Isaacs C, Lamerato L, Reding D, Prorok PC, Berg CD; PLCO Project Team.

J Natl Cancer Inst. 2012 Feb 22;104(4):280-9. doi: 10.1093/jnci/djr549. Epub 2012 Jan 31.

46.

Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up.

Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, Chia D, Church TR, Fouad MN, Isaacs C, Kvale PA, Reding DJ, Weissfeld JL, Yokochi LA, O'Brien B, Ragard LR, Clapp JD, Rathmell JM, Riley TL, Hsing AW, Izmirlian G, Pinsky PF, Kramer BS, Miller AB, Gohagan JK, Prorok PC; PLCO Project Team.

J Natl Cancer Inst. 2012 Jan 18;104(2):125-32. doi: 10.1093/jnci/djr500. Epub 2012 Jan 6.

47.

Longitudinal evaluation of CA-125 velocity and prediction of ovarian cancer.

Xu JL, Commins J, Partridge E, Riley TL, Prorok PC, Johnson CC, Buys SS.

Gynecol Oncol. 2012 Apr;125(1):70-4. doi: 10.1016/j.ygyno.2011.12.440. Epub 2011 Dec 22.

48.

Factors associated with inadequate colorectal cancer screening with flexible sigmoidoscopy.

Laiyemo AO, Doubeni C, Pinsky PF, Doria-Rose VP, Sanderson AK 2nd, Bresalier R, Weissfeld J, Schoen RE, Marcus PM, Prorok PC, Berg CD.

Cancer Epidemiol. 2012 Aug;36(4):395-9. doi: 10.1016/j.canep.2011.10.013. Epub 2011 Nov 22.

49.

Lung cancer screening with low-dose helical CT: results from the National Lung Screening Trial (NLST).

Kramer BS, Berg CD, Aberle DR, Prorok PC.

J Med Screen. 2011;18(3):109-11. doi: 10.1258/jms.2011.011055. No abstract available.

50.

Screening by chest radiograph and lung cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial.

Oken MM, Hocking WG, Kvale PA, Andriole GL, Buys SS, Church TR, Crawford ED, Fouad MN, Isaacs C, Reding DJ, Weissfeld JL, Yokochi LA, O'Brien B, Ragard LR, Rathmell JM, Riley TL, Wright P, Caparaso N, Hu P, Izmirlian G, Pinsky PF, Prorok PC, Kramer BS, Miller AB, Gohagan JK, Berg CD; PLCO Project Team.

JAMA. 2011 Nov 2;306(17):1865-73. doi: 10.1001/jama.2011.1591. Epub 2011 Oct 26.

PMID:
22031728

Supplemental Content

Loading ...
Support Center